The new approval was granted on the basis of results from the phase 3 METEOR trial, which compared cabozantinib with everolimus (Afinitor, Novartis), a standard of care for second-line RCC. SUGGESTED for you Median progression-free survival, the trial's primary outcome, was better with cabozant...
Conclusions: We described second or subsequent line cabozantinib treatment for RCC in a real-world setting and the economic burden of disease in Italy, taking advantage of large, integrated administrative databases.Lolli, CristianVerde, Antonio
It is FDA approved for use in medullary thyroid cancer and as a second-line agent in advanced renal cell carcinoma. In vitro studies found it to exhibit excellent activity against both the wild-type ROS1 fusion and the G2032R and G2026M mutations at concentrations less than 30?nmol/L—a...
Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study Article Open access 23 November 2023 Data availability RNA-seq data have been deposited to the NCBI Gene Expression Omnibus database under...
The cycles of ipilimumab administration were 7 for the first line, 22 for the second line, 13 for the third line, and 58 for the fourth line in the combination arm vs 6 for the first line, 7 for the second line, 13 for the third line, and 74 for the fourth line in the placebo ...
Health Canada approves CABOMETYXTM (cabozantinib) Giving Physicians and Adult Patients a New Second-Line Option in the Fight Against Advanced Hepatocellular Carcinoma Oncology 15 October 2019 4 mins read Health Canada Approves...
First-Line Treatment Cabozantinibwas compared withsunitinibin previously untreated patients with advancedRCCin a phase II trial. 157 patients were randomized 1:1 ratio to receive either cabozantanib 60mg daily, or sunitinib 50mg in a 4/2 schedule (Choueiri et al., 2017).Dose reductionsin both ...
Eighty-seven percent of patients were identified as International Metastatic RCC Database Consortium intermediate or poor risk, and 75% had received cabozantinib in the second- or later-line setting. Sixty-five percent of patients in cohort 1 received prior brain-directed therapy, such as radiation...
This is particularly important, as OS benefit has been elusive in nearly all other prior RCC clinical trials, Motzer notes. Currently, the agent is widely used in the second- and third-line settings, Motzer explains. As such, it was expected that the combination of cabozantinib plus nivolumab...
In addition to its RCC indications, CABOMETYX®is also indicated for the second line treatment of patients with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. The Health Canada approval, achieved in November 2019, was based on results from the CELESTIAL pha...